1,002
Participants
Start Date
September 26, 2021
Primary Completion Date
December 15, 2023
Study Completion Date
December 15, 2023
secukinumab
There is no treatment allocation. Patients administered secukinumab by prescription that have started before inclusion of the patient into the study will be enrolled.
Novartis Investigative Site, Beijing
Novartis Investigative Site, Yinchuan
Novartis Investigative Site, Xicheng Direct
Novartis Investigative Site, Beijing
Novartis Investigative Site, Shanyang
Novartis Investigative Site, Changchun
Novartis Investigative Site, Shanghai
Novartis Investigative Site, Shanghai
Novartis Investigative Site, Shanghai
Novartis Investigative Site, Shanghai
Novartis Investigative Site, Nanjing
Novartis Investigative Site, Suzhou
Novartis Investigative Site, Xuzhou
Novartis Investigative Site, Jinan
Novartis Investigative Site, Jinan
Novartis Investigative Site, Jinan
Novartis Investigative Site, Qingdo
Novartis Investigative Site, Tianjin
Novartis Investigative Site, Tianjin
Novartis Investigative Site, Zhejiang
Novartis Investigative Site, Wenzhou
Novartis Investigative Site, Chongqing
Novartis Investigative Site, Chongqing
Novartis Investigative Site, Changsha
Novartis Investigative Site, Changsha
Novartis Investigative Site, Wuhan
Novartis Investigative Site, Wuhan
Novartis Investigative Site, Zhengzhou
Novartis Investigative Site, Guangzhou
Novartis Investigative Site, Guangdong
Novartis Investigative Site, Shenzhen
Novartis Investigative Site, Shenzhen
Novartis Investigative Site, Haikou
Novartis Investigative Site, Chengdu
Novartis Investigative Site, Chengdu
Novartis Investigative Site, Xian
Novartis Investigative Site, Xi’an
Novartis Investigative Site, Lanzhou
Novartis Investigative Site, Ürümqi
Novartis Investigative Site, Ürümqi
Novartis Investigative Site, Handan
Novartis Investigative Site, Taiyuan
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY